e-ISSN: Pending
Negative / Null Result ReportOpen accessTherapeutics. Pharmacology

Drug Interaction Potential of Berberine Hydrochloride When Co-Administered with Tofacitinib and Filgotinib in Rats

Wang J; Lu S; Zhang C; Wang J; Wu H; Li G · 2025 · Drug Design, Development and Therapy

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Jinglong Wang, Shijia Lu, Chenxiao Zhang, Junjie Wang, Huiru Wu, Guofei Li Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, People’s Republic of ChinaCorrespondence: Guofei Li, Department of Pharmacy, Shengjing Hospital of China Medical University, No. 36, Sanhao Street, Shenyang, 110004, People’s Republic of China, Tel/Fax +86-24-23925108, Email sylgf2009@163.comPropose: The co-treatment of ulcerative colitis with berberine hydrochloride (BBR), the Janus kinase(JAK) inhibitor Tofacitinib (TOFA), and Fligotinib (FIGA) is feasible and sophisti

Abstract by Wang J; Lu S; Zhang C; Wang J; Wu H; Li G, Drug Design, Development and Therapy (2025) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ